English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduResearchers at the NCI-Designated Cancer Center at Sanford Burnham Prebys describe two enzymes newly identified for their roles in regulating macropinocytosis, a process cancer cells use to snatch extra nutrients from the jelly-like substance between cells. This allows tumors to fuel their growth even when they consume more energy and other resources than they can acquire from nearby blood vessels.
Tag: Pancreatic Cancer
More Cancers Are Being Treated with Personalized Therapies Before Surgery
The first-ever annual report from the American College of Surgeons National Cancer Database includes in-depth data on adult cancer diagnoses and treatment trends.
Drug Combination Prompts Immune Response in Some Resistant Pancreatic Cancers
A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center and Oregon Health & Science University.
SLU Study: Integrative Palliative Care Critical to Improve Mental Health Among Pancreatic Cancer Patients
For patients facing a pancreatic cancer diagnosis, a compassionate approach to care can be transformative. Yet, a new study published in Healthcare reveals that palliative care, a service focused on enhancing the quality of life for those with serious illnesses, remains significantly underutilized among pancreatic cancer patients in the United States.
IU researchers map pancreatic cancer tumor neighborhoods
Researchers have mapped pancreatic cancer tumor ecosystems using tissue from both the primary tumor and metastatic disease. The study uncovers notable differences that could lead to new treatment strategies for the often-deadly disease.
Researchers reverse drug resistance in pancreatic cancer model
Cancer cells frequently overhaul their surroundings, making tumors stiffer than nearby healthy tissue. While tumor stiffening makes some cancers easier to detect — this is why physicians feel for hard lumps in the body — it can also ramp up tumor growth and drug resistance. New research suggests that these detrimental changes are not set in stone, however.
MD Anderson Research Highlights for September 19, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
New Study in JNCCN Supports Chemotherapy Option That Reduces Side Effects for People with Gastrointestinal Cancers
New research just-published online by JNCCN—Journal of the National Comprehensive Cancer Network finds that for many commonly used treatment regimens targeting metastatic GI cancers, it is possible to administer 5-FU solely through continuous infusion, minus the bolus component, without negatively affecting patient outcomes.
ASTRO 2024 Tip Sheet From Sylvester Comprehensive Cancer Center
Research findings from Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami will be presented at ASTRO 2024 – the American Society for Radiation Oncology’s annual meeting Sept. 29 – Oct. 2 in Washington D.C. Below are titles for oral presentations, posters and special sessions in which our researchers will be involved.
MD Anderson Research Highlights for August 7, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson include insights into evolutionary cellular adaptations to environmental stressors, potential targets to overcome trouble swallowing in head and neck cancer patients treated with radiation therapy, a promising chemotherapy-free combination treatment for patients with a subset of acute lymphocytic leukemia, a single-cell atlas for stomach cancer metastasis, encouraging results of a PARP inhibitor on patients with advanced cancers and specific DNA damage repair mutations, and a liquid biopsy signature that could improve early pancreatic cancer detection.
Adding metastasis-directed radiation therapy boosts progression-free survival in metastatic pancreatic cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy improved progression-free survival (PFS) in patients with oligometastatic pancreatic cancer.
MD Anderson Research Highlights for July 24, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Pancreatic cancer is difficult to treat. Nano-drugs hitching a ride on bacteria could help.
Many pancreatic tumors are like malignant fortresses, surrounded by a dense matrix of collagen and other tissue that shields them from immune cells and immunotherapies that have been effective in treating other cancers. Employing bacteria to infiltrate that cancerous fortification and deliver these drugs could aid treatment for pancreatic cancer, according to newly published findings from a team of University of Wisconsin–Madison researchers.
Could the liver hold the key to better cancer treatments?
Liver inflammation, a common side-effect of cancers elsewhere in the body, has long been associated with worse cancer outcomes and more recently associated with poor response to immunotherapy. Now, a team led by researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania has found a big reason why.
New Findings in JNCCN Illustrate Pathway for Screening High-Risk Individuals for Pancreatic Cancer in PRECEDE Study
New research in the April 2024 issue of JNCCN—Journal of the National Comprehensive Cancer Network showcases the feasibility of improving early detection and prevention for pancreatic cancer.
MD Anderson Research Highlights for March 20, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Hackensack Meridian Jersey Shore University Medical Center Welcomes Dr. Lee Peng as Chief of Gastroenterology
Hackensack Meridian Jersey Shore University Medical Center welcomed Lee F. Peng, M.D., PhD, as section chief of gastroenterology, department of medicine.
NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and other Cancer Types Based on Emerging Evidence
Recent NCCN Guidelines updates—along with the supporting evidence—will be presented during the NCCN 2024 Annual Conference held in Orlando, Florida April 5-7, and simultaneously online. Visit NCCN.org/conference to learn more and register.
Researchers makes promising discoveries on role of vitamin B6 in pancreatic cancer
Vitamin B6 is beneficial in many ways, notably for its role in maintaining a strong immune system.
Age-Related Changes in Fibroblast Cells Promote Pancreatic Cancer Growth and Spread
Older people may be at greater risk of developing pancreatic cancer and have poorer prognoses because of age-related changes in cells in the pancreas called fibroblasts, according to research led by investigators from the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins Bloomberg School of Public Health and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.
UCLA-led research results in FDA approval of 4-drug combination for frontline treatment of metastatic pancreatic cancer
A four-drug chemotherapy regimen of irinotecan liposome (Onivyde) in combination with oxaliplatin, leucovorin, and fluorouracil has been approved by the FDA for the first-line treatment of metastatic pancreatic adenocarcinoma.
Pancreatic cancer hijacks a brain-building protein
Scientists at Cold Spring Harbor Laboratory (CSHL) and the University of California, Davis have reached a new breakthrough in pancreatic cancer research—eight years in the making.
Expert from Rutgers Cancer Institute of New Jersey available for comment on FDA approval for NALIRIFOX: a new first-line treatment for patients with metastatic pancreatic cancer
On February 13, 2024, the Food and Drug Administration approved NALIRIFOX, a combonation chemotherapy, for the first-line treatment of metastatic pancreatic adenocarcinoma. Patrick Boland, MD, is a medical oncologist in the Gastrointestinal Oncology Program at Rutgers Cancer Institute of New…
MD Anderson Research Highlights for February 7, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
New Potential Immunotherapies for Pancreatic Cancer
Pancreatic cancer can be a devastating diagnosis due to its extremely aggressive nature and low survival rate.
High insulin levels directly linked to pancreatic cancer
First detailed explanation of why people with obesity and Type 2 diabetes are at an increased risk of pancreatic cancer
MD Anderson Research Highlights for October 25, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments at MD Anderson include positive results from a Phase I trial for patients with TP53-mutant acute myeloid leukemia, a novel machine learning platform to identify cancer biomarkers from liquid biopsies, a tumor-specific multi-microRNA delivery system to improve treatment outcomes in glioblastoma, a combination strategy to overcome treatment resistance in KRAS-mutated pancreatic cancer, and a new target for improving treatment response in patients with stomach cancer that has metastasized to the peritoneal cavity.
A Cancer Survival Calculator Is Being Developed Using Artificial Intelligence
Researchers have developed an artificial intelligence (AI)–based tool for estimating a newly diagnosed cancer patient’s chances for surviving long term, according to a study presented at the American College of Surgeons (ACS) Clinical Congress 2023.
New study suggests promising approach for treating pancreatic cancer
A new study carried out in mice, led by Queen Mary University of London, has identified cells that drive the spread of pancreatic cancer and discovered a weakness in these cells that could be targeted using existing drugs. This offers a promising new approach for treating pancreatic cancer.
Copycat nutrient leaves pancreatic tumors starving
A study led by scientists at Sanford Burnham Prebys suggests an entirely new approach to treat pancreatic cancer. The research shows that feeding tumors a copycat of an important nutrient starves them of the fuel they need to survive and grow.
Newfound mechanism suggests drug combination could starve pancreatic cancer
A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.
MD Anderson Research Highlights for October 4, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson include a computer game that helps breast cancer survivors improve symptoms of peripheral neuropathy, a publicly available single-cell atlas of CD19 chimeric antigen receptor (CAR) T cells, new targets for TP53-mutant acute myeloid leukemia (AML), a preclinical target for preventing chemobrain, a blood test to help identify patients at higher risk of developing pancreatic cancer, and genomic insights to predict the risk of outcomes in patients with bone cancer.
Mayo Clinic’s AI innovation inspires hope in early detection of pancreatic cancer
Estimated to become the second leading cause of cancer deaths in the U.S. by 2030, pancreatic cancer has a grim prognosis with nearly 70% of patients facing mortality within the first year of diagnosis. Unfortunately, 40% of small pancreatic cancers elude detection on CT scans until they’ve advanced to an incurable stage.
The Cancer Research Institute and the Lustgarten Foundation Announce INSPIRE Partnership to Jointly Support Pancreatic Cancer Immunotherapy Research
The Cancer Research Institute and the Lustgarten Foundation Announce INSPIRE Partnership to Jointly Support Pancreatic Cancer Immunotherapy Research
US Department of Defense backs Cosimo Commisso’s pancreatic cancer research
Cosimo Commisso, Ph.D., has received a grant from the Department of Defense for $1 million to advance the research of a small molecule that kills pancreatic cancer cells by disrupting their pH equilibrium.
Pancreatic cancer research in vaccines, immune-based therapies and KRAS inhibition funded by The Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network (PanCAN), a leading non-profit in the fight against pancreatic cancer, has awarded Dana-Farber Cancer Institute researchers William Freed-Pastor, MD, PhD, and Julien Dilly, MS, research grants of $250,000 and $150,000, respectively over a 2-year period, to support their crucial work in the field of pancreatic cancer research.
Sylvester Surgeon-Scientist Awarded Center’s First Department of Defense Grant to Study Pancreatic Cancer
Researchers with Sylvester Comprehensive Cancer Center have been awarded a three-year, $800,000 grant from the U.S. Department of Defense (DoD)’s Congressionally Directed Medical Research Program to target chemotherapy resistance in pancreatic cancer.
Sylvester Comprehensive Cancer Center Tip Sheet – August 2023
New research shows blood cancers are often misdiagnosed, an NCI grant to develop a urine test for prostate cancer, a surgeon-scientist receives Sylvester’s first DoD grant to study pancreatic cancer, bolstering emergency preparedness for climate-driven disasters, and more are included in this month’s tip sheet .
In battle against pancreatic cancer, grant-funded H-FIRE study offers hope
The National Institutes of Health has awarded $2.6 million to a Virginia Tech team over five years for a study of high frequency irreversible electroporation (H-FIRE) for tumor ablation and immune system activation in cases of pancreatic cancer.
MD Anderson Research Highlights for August 2, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments include a novel biomarker that may predict the aggressiveness of pancreatic cancer precursors, insights into the structure and function of a breast and ovarian cancer susceptibility gene, a new approach to overcoming treatment resistance in ovarian cancer, distinguishing features of young-onset rectal cancer, a biomarker and potential target for metastatic lung cancer, machine learning models to better predict outcomes of patients with mantle cell lymphoma (MCL), and a promising therapy for patients with relapsed/refractory MCL.
Pancreatic Cancer Starts with Mutant Cells Affecting Ion Balance and Energy Production
Rockville, Md. (July 26, 2023)—Mutant cells that initially resemble normal enzyme-producing cells drive the development of pancreatic cancer, according to a new study in the journal Function. One key distinction is that mutant cells might show altered physiological characteristics early…
Pancreatic Cancer Risk Lower if Pancreatic Cysts Remain Stable for Five Years
Low-risk branch duct intraductal papillary mucinous neoplasms (IPMN) are the most common precancerous form of mucinous pancreatic cysts and once identified require regular surveillance imaging. But consensus is still forming around how long that watchful period should last.
Staging pancreatic cancer early with minimally invasive surgery shows positive results in patient prognosis, Mayo Clinic study finds
A study published in the Journal of the American College of Surgeons reveals that performing a minor surgical procedure on patients newly diagnosed with pancreatic cancer helps to identify cancer spread early and determine the stage of cancer.
One-Two Punch: Novel Drug Pairing Could Beat Pancreatic Cancer
UC San Diego researchers find a combination of drugs outperformed other treatments in human and mouse models of pancreatic cancer; now urge clinical trial.
UTHealth Houston study on repeated radiofrequency ablation in combination with chemotherapy for pancreatic cancer supported with $3.3M HHS grant
A combination strategy of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) with chemotherapy for pancreatic cancer will be studied at UTHealth Houston through a $3.3 million grant from the National Cancer Institute by the U.S. Department of Health and Human Services.
Implantable device shrinks pancreatic tumors
Houston Methodist nanomedicine researchers have found a way to tame pancreatic cancer – one of the most aggressive and difficult to treat cancers – by delivering immunotherapy directly into the tumor with a device that is smaller than a grain of rice.
Cedars-Sinai Cancer Experts To Present Clinical Findings at AACR Conference
Cedars-Sinai Cancer oncologists and researchers are available to comment on late-breaking topics and research throughout the American Association for Cancer Research (AACR) Annual Meeting 2023, happening April 14-19 in Orlando.
UTEP to Investigate Pancreatic Cancer Risk Factors with $1M NIH Grant
The University of Texas at El Paso will undertake potentially transformative research on how specific risk factors promote pancreatic cancer development with support from a $1 million grant from the National Institutes of Health’s National Cancer Institute.
Sanford Burnham Prebys researchers awarded $2.6M to discover pancreatic cancer drugs
Cosimo Commisso, Ph.D., and Susanne Heynen-Genel, Ph.D., have received a grant from the National Cancer Institute (NCI) to advance a new treatment approach for pancreatic cancer.
MD Anderson Research Highlights for March 8, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.